Results 301 to 310 of about 279,323 (388)
Abstract Objective/Background This study was undertaken to assess participants' impression of use and satisfaction with STS101 in a long‐term, open‐label safety study. The ASCEND study assessed the safety and tolerability of STS101, an investigational drug–device combination of 5.2 mg dihydroergotamine in a single‐use nasal delivery device for the ...
Jessica Ailani +4 more
wiley +1 more source
Significantly Positive Impact of Nonsteroidal Anti-inflammatory Drugs Combined With Osmoprotectant (Osmolytes) in Cancer Treatment. [PDF]
Basheeruddin M, Qausain S.
europepmc +1 more source
Abstract Objective This study evaluated the pharmacokinetics of zavegepant in human breast milk and plasma following a single, 10 mg dose of zavegepant nasal spray. Background Zavegepant nasal spray is a member of the gepant class of medications; small molecule inhibitors of the calcitonin gene‐related peptide receptor.
Abhijeet Jakate +9 more
wiley +1 more source
Preemptive oral analgesia with steroidal and nonsteroidal anti-inflammatory drugs in periodontal surgery: a systematic review. [PDF]
Lages LPD +6 more
europepmc +1 more source
Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami +6 more
wiley +1 more source
Nonsteroidal Anti-Inflammatory Drugs Decrease Coagulopathy Incidence in Severe Burn Patients. [PDF]
Huang L +10 more
europepmc +1 more source
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui +15 more
wiley +1 more source
A graphical abstract recapping the different sources of dental, periodontal, and other oral‐derived mesenchymal stromal cells (MSCs) and their regenerative mechanisms and potentials. The review's article findings bridge fundamental biological science with translational advances, highlighting the significance of MSCs in craniofacial regenerative ...
Karim M. Fawzy El‐Sayed +6 more
wiley +1 more source

